Long-term weight loss for patients with obesity proved mostly successful after taking prescription-only injectable ...

Few medications have become as popular and culturally relevant as Ozempic has, but how exactly do it and similar drugs affect ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Plus: The story behind the award-winning science that led to Ozempic, the next astronaut launch and why homework is good for ...

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

Hims & Hers Health will offer compounded GLP-1 weight-loss medications for as low as $99 per month to eligible U.S. military ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

The study concentrates on the FDA-approved injectable medications semaglutide and liraglutide. A study conducted by the ...

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analog class, better ...

Injectable prescription drugs that reduce appetite — like Ozempic, Saxenda and Mounjaro — have skyrocketed in popularity in ...

People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...

Novo Nordisk’s NVO oral obesity pill, amycretin, showed faster weight loss than its blockbuster weekly injection, Wegovy (semaglutide), in a phase I study. Not only did NVO’s stock rise 4% in response ...